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has been a developing trend toward the identification of 
lead compounds with good therapeutic importance, but 
fail to elicit their maximum therapeutic effects because of 
poor aqueous solubility. While these attributes conspire to 
provide optimized drug-receptor binding characteristics, 
they also tend to result in poor drug solubility and poor 
membrane permeability characteristics. As solubility 
and permeability are considered prerequisites to oral 
absorption, many of these drugs exhibit poor and variable 
bioavailability.[1] Such drugs may be recognized by a high-
dose-to-solubility ratio, and bioavailability is frequently 
increased by coadministration of food.[2,3]
The oral delivery of such drugs is frequently associated 
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The advent of combinatorial chemistry and high-
throughput screening has resulted in the rapid identification 
of many highly potent new chemical entities. Coincident 
with the increasing use of these technologies, however, 
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ABSTRACT
Flutamide (FLT) is an antiandrogen drug for the treatment of prostate cancer. It has the drawback of poor water 
solubility and needs enhancement of its dissolution rate in simulated gastric fluids. Hence, it is prepared as self-
nanoemulsifying drug delivery systems (SNEDDS) with an aim to enhance its dissolution rate. The objectives 
of the study are to develop SNEDDS of FLT and to characterize for particle size, self-nanoemulsification, and 
dissolution enhancement. Solubility of FLT was determined in various oils, surfactants, and cosurfactants. Sesame 
oil was selected as an oil phase, Tween 20 as surfactant, and PEG400 as cosurfactant due to their higher 
solubilization effect. Various formulations were prepared by simple mixing followed by vortexing. From studies, 
the optimized SNEDDS formulation was composed of FLT (8.04% w/w), sesame oil (24.12% w/w), Tween 20 
(53.38% w/w), and PEG400 (14.46% w/w). The selected SNEDDS could be self-emulsified without precipitation 
upon simple mixing. The mean particle size of the SNEDDS was 148.7 nm and percent drug content was 99.66. 
The dissolution rate of FLT from SNEDDS was faster and higher in three different dissolution media such as 
2% sodium lauryl sulfate (97.85%), simulated gastric fluid (0.1 N HCl containing 0.5% Tween 20) (95.71%), and 
simulated intestinal fluid (pH 6.8 buffer) (96.21%).
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with implications of low bioavailability, high intra- and 
intersubject variability, and lack of dose proportionality.[4]
To overcome such problems, various formulation 
strategies are reported in the literature including the use of 
surfactants, cyclodextrins, solid dispersions, micronization, 
permeation enhancers, and lipids.[5]
Lipid-based formulations such as self-emulsifying drug 
delivery systems (SEDDS) have been shown to enhance 
oral absorption of lipophilic drugs.[6] Although the exact 
mechanisms responsible for this enhanced absorption 
are not fully known, it is believed that factors including 
improved drug solubilization, increased membrane 
permeability, and lymphatic transport may make significant 
contributions.[7,8]
Self-nanoemulsifying drug delivery systems are isotropic 
mixtures of oil, surfactant, cosurfactant, and drug that 
form fine oil-in-water nanoemulsion when introduced 
into aqueous phases under conditions of gentle agitation.[9]
This property renders SNEDDS a good candidate for oral 
delivery of hydrophobic drugs with adequate solubility in 
oils or oil/surfactant blends.[10-12]
Because of self-emulsification in the stomach, the drug 
is presented as small droplets of oil (<5 µm) leading to 
improved drug dissolution through providing a large 
interfacial surface area for partitioning of the drug 
between the oil and GIT fluid.[13] Other advantages include 
increased stability of drug molecules, and the possibility of 
administering the final product as gelatin capsules.[6] For 
drugs subjected to dissolution rate-limiting absorption, 
SNEDDS presents a possibility for enhancement in 
both the rate and extent of drug absorption and the 
reproducibility of the plasma concentration profile.[14-16]
An example of a commercially available SEDDS is 
cyclosporine, Neoral®, resulted in a twofold increase 
in its bioavailability in humans compared with other 
cyclosporine formulations.[17] Selection of a suitable self-
emulsifying formulation depends upon the assessment of 
the solubility of the drug in various components and the 
droplet size distribution of resultant emulsion following 
self-emulsification.[10]
Flutamide is a nonsteroidal antiandrogen and chemically 
it is 2-methyl-N-[4-nitro-3 (trifluoromethyl) phenyl] 
propanamide.[18] In humans, FLT has low oral bioavailability 
due to poor wettability and low aqueous solubility, poor 
permeability, and rapid first pass hepatic extraction.[19] Thus, 
we have proposed to formulate a lipid-based system of 
FLT to enhance its dissolution rate to achieve optimum 
oral bioavailability. The main objectives of the study were 
to develop and evaluate an optimal SNEDDS formulation 
of FLT.
MATERIALS AND METHODS
FLT was purchased from M/s Unichem Laboratories 
Ltd., Raigad, India. Gelatin capsules, No. 0, were kindly 
supplied by KAPL, Bangalore. All other chemicals, Tween 
80 (polyoxyethylene sorbitan monooleate), Tween 20 
(polyoxyethylene sorbitan monolaurate), and PEG 400 
were obtained from Merck, Mumbai. Span 80 (sorbitan 
monooleate), span 20 (sorbitan monolaurate), and 
propylene glycol were obtained from S.D. Fine-chemicals 
Limited, Mumbai. All the other chemicals were of analytical 
grade.
Solubility studies
The solubility of FLT in various oils, surfactants, and 
cosurfactants was determined as given in Table 1. An excess 
amount of FLT was added into each vial containing 10 mL 
of selected vehicle. Then, the mixture was heated at 40 °C 
in a water bath to facilitate the solubilization. Mixing of 
the systems was performed using a cyclo mixer (CM 101, 
Remi, India) for 10 min in order to facilitate proper mixing 
of drug with the vehicles. Then, the formed suspensions 
were shaken for 48 h in a mechanical shaker (Remi, India). 
After reaching equilibrium, the mixtures were centrifuged 
at 2500g for 20 min to remove undissolved FLT, followed 
by filtration through a 0.45-µm millipore membrane 
filter paper. The supernatant was taken and diluted with 
methanol, and FLT dissolved in various vehicles was 
quantified by a validated HPLC method (Shimadzu HPLC, 
class VP series, Japan) with two CC-10 AT VP pumps and 
class VP software.
Preparation of SNEDDS formulations
On the basis of the “Solubility studies” section, the oil 
Table 1: Solubility of flutamide in various vehicles at 25 
°C (n = 3)
Vehicle Solubility (mg/mL) % Solubility (w/v)
Sesame oil 0.912 ± 0.008 91.2
Olive oil 0.623 ± 0.027 62.3
Sunflower	oil 0.53 ± 0.031 53.0
Tween 80 0.692 ± 0.018 69.2
Tween 20 0.905 ± 0.035 90.5
Span 20 0.55 ± 0.053 55.0
Span 80 0.438 ± 0.017 43.8
Polyethylene glycol 400 0.747 ± 0.041 74.7
Propylene glycol 0.71 ± 0.05 71.0
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(sesame oil), surfactant (Tween 20), and cosurfactants 
(PEG 400) were selected due to their greater solubility 
enhancement effect on FLT. Various formulations were 
tried as shown in Table 2. The formulations were prepared 
by dissolving FLT (8.04% w/w) in the mixture of oil, 
surfactant, and cosurfactant and were heated at 50 °C in 
an isothermal water bath. This mixture was mixed well and 
subjected to vortexing using cyclomixer (Remi, India), until 
a transparent preparation was obtained. All the mixtures 
were stored at ambient temperature for further use.
Characterization and evaluation of SNEDDS
Self-emulsification and precipitation assessment
In brief, various compositions were categorized on the 
basis of clarity and apparent stability of the resultant 
emulsion. Visual assessment was performed by dropwise 
addition of the preconcentrate (SNEDDS) into 250 mL of 
distilled water taken in a glass beaker at room temperature. 
The contents were gently stirred either using glass rod or 
magnetically at ~100 rpm. They were observed immediately 
after dilution for assessment for self-nanoemulsification 
efficiency, appearance (transparency), phase separation, 
and precipitation of drug.
Precipitation was evaluated by visual inspection of the 
resultant nanoemulsion after 24 h. The formulation were 
then categorized as clear (transparent or transparent with 
bluish tinge), nonclear (turbid), stable (no precipitation 
at the end of 24 h), or unstable (showing precipitation 
within 24 h).
Emulsion droplet size analysis/particle size determination
The selected formulation, F5 that indicated self-
emulsification and nonprecipitation was subject to droplet 
size analysis. The formulation, 100 µL was diluted to 250 
mL in a beaker and gently mixed using a glass rod. The 
resultant emulsion was then subjected to particle size 
analysis using Malvern zetasizer (Malvern, UK). All studies 
were repeated for six times, with good agreement being 
found between measurements.
Percent drug content estimation
Flutamide from preweighed SNEDDS was extracted 
by dissolving in 20 mL methanol. FLT content in the 
methanolic extract was analyzed using UV-Visible 
spectrophotometer (Systronics) at 306 nm, against the 
solvent blank.
Zeta potential determination
The zeta potential ζ of the diluted SNEDDS formulations 
was measured using a Malvern zetasizer (Malvern, UK). 
The SNEDDS were diluted with a ratio of 1:2500 (v/v) 
with distilled water and mixed for 1 min using a magnetic 
stirrer. Zeta potential of each SNEDDS was determined 
in triplicate.
In vitro drug release studies
SNEDDS of FLT was filled in size “0” hard gelatin 
capsules and used for drug release studies. The in vitro 
drug release studies were also conducted for plain FLT for 
the comparison of results. The quantitative in vitro release 
test was performed using USP dissolution apparatus II 
(Elecrtolab, India). The paddles were rotated at 75 rpm. 
Dissolution studies were run using 900 mL of three 
different media such as 2% sodium lauryl sulfate, simulated 
gastric fluid (0.1 N HCl containing 0.5% of Tween 20), 
and simulated intestinal fluid (pH 6.8 buffer). No enzymes 
were added to the media. The temperature was set at 37 
± 0.5 °C. During the release studies, a 5-mL sample of 
medium was taken out and estimated for drug content 
using UV-Visible spectrophotometer (Systronics) at 306 
nm against the solvent blank. The removed volume was 
replaced each time with 5 mL of fresh medium to maintain 
sink conditions. The samples were withdrawn at 10, 20, 30, 
40, 50, and 60 min. Each study was conducted in triplicate.
RESULTS AND DISCUSSION
Solubility studies
Solubility studies were performed to identify suitable oily 
phase, surfactants, and cosurfactants for the development 
of SNEDDS of FLT. Because an important consideration 
when formulating a self-emulsifying formulation is avoiding 
precipitation of the drug on dilution in the gut lumen in 
vivo.[6] The components used in the system should have 
high-solubilization capacity for the drug, ensuring the 
solubilization of the drug in the resultant dispersion.
The results of solubility studies are reported in Table 1 
and Figure 1. It is evident from the results that, among 
oils, sesame oil (0.912 ± 0.008 mg/mL) exhibited the 
highest solubilization capacity for the drug FLT, and among 
surfactants, Tween 20 (0.905 ± 0.035 mg/mL) showed the 
highest solubility followed by PEG 400 (0.747 ± 0.041 
Table 2: Composition of self-nanoemulsifying drug 
delivery systems formulations of flutamide
Ingredients 
(% w/w)
F1 F2 F3 F4 F5
Flutamide 8.04 8.04 8.04 8.04 8.04
Sesame oil 38.85 36.32 33.59 29.75 24.12
Tween 20 39.83 41.79 44.25 48.76 53.38
PEG 400 13.28 13.85 14.12 13.45 14.46
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Self-nanoemulsifying drug delivery system of flutamide 
mg/mL) among cosurfactants. Hence, for the preparation 
of SNEDDS, sesame oil, Tween 20, and PEG 400 were 
chosen as an oil, surfactant, and cosurfactant.
Preparation of SNEDDS for FLT
Several SNEDDS systems with the ability to dissolve 50 mg 
of FLT were prepared and compared. During preliminary 
study, some SNEDDS were eliminated due to detection 
of oil droplets on the surface of the diluted SNEDDS, 
which translates to an incomplete emulsification. SNEDDS 
that were not able to self-emulsify upon mixing with water 
under mild-agitation or yielded an unstable emulsions were 
rejected. A few SNEDDS formulations were eliminated due 
to the formation of milky emulsions upon dilution. The 
transparency of the diluted SNEDDS reflects the proximity 
of the droplet size to that of the nanoemulsion range. 
Formulations, F1-F5 which were obtained transparent 
were given in Table 2, and they were subjected to test for 
self-emulsification and precipitation assessment.
Self-emulsification and precipitation assessment
Evaluation of self-nanoemulsifying properties of 
SNEDDS formulations was performed by visual 
assessment as reported.[20] These studies were carried out 
on various SNEDDS formulations. During the study, it 
was found that some formulations, F1 and F2 showed 
turbidity, precipitation and thus was not stable, due to 
the relative decrease in surfactant concentration and the 
presence of PEG 400. Hence, F3, F4, and F5 were prepared 
with increased concentrations of surfactant. Formulation 
F5 could be mixed with sesame oil, Tween 20, and PEG 
400 and hence was selected as good formulation and 
subjected to further investigation regarding droplet size, 
Zeta potential, etc.
Evaluation of SNEDDS for droplet size analysis, zeta 
potential, and drug content determination
Droplet size distribution following self-nanoemulsification 
is a critical factor to evaluate a self-nanoemulsion system. 
The mean globule size of selected SNEDDS formulation 
F5, of FLT was 148.7 nm [Table 3] is indicated the ability 
of the present technology to produce nanoemulsion 
that offers larger interfacial surface area required for 
drug absorption.[21,22] An increase in the ratio of the oily 
phase (sesame oil) resulted in a proportional increase in 
particle size, because of the simultaneous decrease in 
the s/cos proportion. Increasing the s/cos (surfactant to 
cosurfactant) ratio led to decrease in mean droplet size. 
The optimized SNEDDS, with the highest proportion 
of surfactant (53.38% w/w Tween 20) at a fixed amount 
of oil (24.12% w/w), was produced lowest mean particle 
diameter of 148.7 nm. This could be attributed to an 
increased surfactant proportion relative to cosurfactant.
The optimized SNEDDS showed high absolute zeta 
potential value of -28.7 mv. The emulsion stability is 
directly related to the magnitude of the surface charge.[23-25]
Generally, an increase of electrostatic repulsive forces 
between nanoemulsion droplets prevents the coalescence 
of droplets. On the contrary, a decrease of electrostatic 
repulsive forces will cause phase separation. The results of 
zeta potential and drug content estimation are indicated 
in Table 3. The percent drug content (99.66 ± 5.2) of 
SNEDDS of FLT was found satisfactory.
In vitro drug release study
To understand the characteristics of drug release from 
SNEDDs, an in vitro release study was carried out for pure 
drug and SNEDDs of FLT in different dissolution media 
such as 2% sodium lauryl sulfate, simulated gastric fluid 
(0.1 N HCl containing 0.5% of Tween 20), and simulated 
intestinal fluid (pH 6.8 buffer). The dissolution profiles 
of pure drug and SNEDDS formulation are shown in 
Figure 2. As evident from the drug release profiles, the 
pure drug evidenced meager solubility of 27.48% in 60 
min in 2% SLS, 20.7% in 0.1 N HCl containing 0.5% of 
Tween 20 and 20.94% in pH 6.8 buffer. The drug release 
from SNEDDS was markedly high such that 97.85% in 

































Table 3: Evaluation parameters of self-nanoemulsifying 
drug delivery systems formulation of flutamide, F5 
(n = 3)
Evaluation parameter Results
Mean droplet size (nm)  148.7 ± 2.325
Mean zeta potential (mv) -28.7 ± 4.62
% Drug found (mg mL-1) 99.66 ± 5.28   Journal of Young Pharmacists Vol 3 / No 1
2% sodium lauryl sulfate, 95.71% in simulated gastric fluid 
(0.1 N HCl containing 0.5% of Tween 20) and 96.21% 
in simulated intestinal fluid (pH 6.8 buffer). The results 
indicate instantaneous and remarkably high dissolution of 
FLT in all three media compared to the pure drug. This 
higher and faster dissolution rate of FLT from SNEDDS is 
expected due to the nanoparticle size range of the particles 
offering higher interfacial area required for dissolution.
CONCLUSION
An optimized SNEDDS formulation of FLT consisting 
of FLT (8.04% w/w), sesame oil (24.12% w/w), Tween 
20 (53.38% w/w), and PEG 400 (14.46% w/w) was 
successfully developed with an increased solubility and 
dissolution rate. The SNEDDS of FLT possessed mean 
nanoparticle size of 148.7 nm and other ideal characteristics 
required for enhanced dissolution rate. Thus, our study 
confirmed that the SNEDDS formulation can be used as 
a possible alternative to traditional oral formulations of 
FLT to improve its dissolution rate leading to enhanced 
bioavailability.
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Figure 2: Comparative results of drug release from plain FLT and 
the SNEDDS formulation in different dissolution media. FLT, Plain 
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